Equities Analysts Offer Predictions for COYA Q3 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for Coya Therapeutics in a research report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.24) for the quarter, up from their previous estimate of ($0.50). The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.41) EPS.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million.

A number of other research firms have also commented on COYA. D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Tuesday, May 13th.

Coya Therapeutics Stock Down 1.8%

Shares of COYA stock opened at $5.86 on Wednesday. The company has a market capitalization of $98.01 million, a P/E ratio of -9.02 and a beta of 0.49. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24. The firm has a 50-day moving average price of $6.02 and a 200 day moving average price of $6.16.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares during the period. Geode Capital Management LLC increased its stake in Coya Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Coya Therapeutics in the first quarter worth $65,000. Finally, XTX Topco Ltd acquired a new stake in Coya Therapeutics in the fourth quarter worth $59,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.